Antiresorptive therapy influence on peri-implant diseases: clinical implications and
By Emilio A. Cafferata, Frank Schwarz, Reinhard Gruber
Originally at onlinelibrary.wiley.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Implantologists, periodontists, and restorative dentists must now weigh antiresorptive drug history when diagnosing peri-implantitis or planning maintenance, because these agents can alter bone turnover and inflammatory responses around implants.
Key points
- Periodontology 2000 EarlyView article links systemic antiresorptive therapy to changes in peri-implant bone remodeling and immune signaling.
- Osteoimmunological pathways modulated by these drugs may influence both progression and healing of peri-implant diseases.
- Clinicians should obtain updated medication histories and consider medical consultation prior to surgical or regenerative interventions around implants.
- Findings reinforce the need for individualized supportive care intervals for patients on bisphosphonates, denosumab, or similar agents.
Who should care
Read the original on Periodontology 2000
Full reporting and any paywall content live on onlinelibrary.wiley.com. We summarize and score; we do not republish.
Related
- ·Research
From mouth to brain: linking periodontal and peri-implant dysbiosis to systemic
- ·Research
Herpes zoster ophthalmicus following endodontic treatment: a case report
- ·Research
Formulation-dependent hydrothermal degradation of ultratranslucent 5y-tzp zirconia
- ·Regulatory
California Expands Access to Fluoride Varnish